Good morning :)
Sun Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries Ltd

SUNPHARMA Share Price

NSE
1,925.300.20% (+3.90)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹4,61,008 cr, stock is ranked 11

Stock is 1.49x as volatile as Nifty

SUNPHARMA Stock Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹4,61,008 cr, stock is ranked 11

Stock is 1.49x as volatile as Nifty

SUNPHARMA Performance & Key Metrics

SUNPHARMA Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
40.165.500.83%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
43.556.170.52%

SUNPHARMA Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
94%
Analysts have suggested that investors can buy this stock

from 32 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

SUNPHARMA Company Profile

Sun Pharmaceutical Industries Limited is a pharmaceuticals company which offers generics, branded generics, specialty products, over-the-counter products, anti-retroviral and APIs.

Investor Presentation

View older View older 

Jul 7, 2026

PDF
View Older Presentations

SUNPHARMA Similar Stocks (Peers)

Compare with peers Compare with peers 

SUNPHARMA Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
77.46
77.46
1Y Return
45.41%
45.41%
Buy Reco %
78.57
78.57
PE Ratio
29.71
29.71
1Y Return
3.86%
3.86%
Buy Reco %
65.71
65.71
PE Ratio
21.37
21.37
1Y Return
29.41%
29.41%
Buy Reco %
55.56
55.56
PE Ratio
22.39
22.39
1Y Return
16.82%
16.82%
Buy Reco %
55.17
55.17
PE Ratio
54.14
54.14
1Y Return
7.01%
7.01%
Buy Reco %
88.24
88.24
Compare with Peers

SUNPHARMA Sentiment Analysis

SUNPHARMA Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

SUNPHARMA Stock Summary · May 2026

Management framed the transaction as a transformative, scale‑creating acquisition that will be EPS‑accretive from day one and is priced at $14.00 per share (about $3.99 billion equity value) with pro‑forma leverage of roughly 2.3x EBITDA. They stressed preserving Organon’s strengths—a roughly 30% EBITDA margin, a ~50‑brand women's‑health portfolio and global manufacturing footprint—while prioritizing cost synergies (targeting about $350 million over two to four years), commercial cross‑selling, selective in‑licensing of pre‑LOE biosimilars and pre‑close regulatory filings to accelerate launches. Management described an integration approach focused on diagnostic assessment, two‑way learning, talent retention and an integration office, and signaled priority on early deleveraging using expected combined free cash flow of about $2.0–$2.5 billion. At the same time they acknowledged tensions including Organon’s limited organic growth and pipeline, balance‑sheet and refinancing considerations tied to roughly $8.5 billion gross debt, and US biosimilars regulatory uncertainty, and they said several disclosure details will be finalized closer to closing; they expect to seek approvals and aim to close in roughly six to nine months.

SUNPHARMA Stock Growth Drivers
SUNPHARMA Stock Growth Drivers
6
  • Transformational acquisition driving scale and higher‑value mix

    Management frames the Organon transaction as a transformational step that materially increases Sun Pharma’s scale

  • High‑quality established brands and women’s‑health leadership

    Organon brings a deep, defendable established‑brand franchise and clear leadership in women’s health that strengthens

SUNPHARMA Stock Challenges
SUNPHARMA Stock Challenges
4
  • Material increase in leverage and refinancing/interest-rate exposure

    The transaction will move the company from a net-cash position to a pro-forma net-debt/EBITDA of

  • Synergy and cash-generation assumptions are preliminary and execution-dependent

    The company cites roughly $350 million of synergies to be realized over two to four

SUNPHARMA Forecast

SUNPHARMA Forecasts

Price

Revenue

Earnings

SUNPHARMA

SUNPHARMA

Income

Balance Sheet

Cash Flow

SUNPHARMA Income Statement

SUNPHARMA Income Statement

Loading...

Quarterdec 2023mar 2024jun 2024sep 2024dec 2024mar 2025jun 2025sep 2025dec 2025mar 2026
Total Revenue12,630.9012,588.8413,185.3013,645.3914,141.0813,571.7114,315.8614,948.2316,099.3815,070.29
Operating & Other expensessubtract8,973.689,049.399,045.139,352.439,982.619,604.4310,367.749,951.2611,061.5310,657.59
Depreciation/Amortizationsubtract622.14650.36655.13625.91630.56663.79700.55729.50732.33775.47
Interest & Other Itemssubtract34.7373.5761.5469.1751.5149.1474.8099.8678.3685.89
Taxes & Other Itemssubtract476.60160.94587.88557.72573.021,104.47894.141,049.66858.35837.31
EPS10.5011.1011.8012.7012.109.009.5013.0014.0011.30

SUNPHARMA Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2027FY 2027

Annual Report Pending

Investor Presentation

Jul 7PDF
FY 2026FY 2026

Annual report

PDF

Investor Presentation

Apr 27PDF
Feb 24PDF
Dec 26PDF
+2 more
FY 2025FY 2025

Annual report

PDF

Investor Presentation

Mar 4PDF
Nov 28PDF
Sep 30PDF
FY 2024FY 2024

Annual report

PDF

Investor Presentation

Sep 11PDF
FY 2023FY 2023

Annual report

PDF
FY 2022FY 2022

Annual report

PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
 

SUNPHARMA Stock Peers

SUNPHARMA Past Performance & Peer Comparison

SUNPHARMA Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Sun Pharmaceutical Industries Ltd40.165.500.83%
Torrent Pharmaceuticals Ltd77.469.530.77%
Cipla Ltd29.713.340.91%
Lupin Ltd21.376.590.72%

SUNPHARMA Stock Price Comparison

Compare SUNPHARMA with any stock or ETF
Compare SUNPHARMA with any stock or ETF
SUNPHARMA
Loading...

SUNPHARMA Holdings

SUNPHARMA Shareholdings

SUNPHARMA Promoter Holdings Trend

SUNPHARMA Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

SUNPHARMA Institutional Holdings Trend

SUNPHARMA Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

SUNPHARMA Shareholding Pattern

SUNPHARMA Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding54.48%11.96%9.15%15.93%8.48%

Jun 2025

Sep 2025

Dec 2025

Mar 2026

SUNPHARMA Shareholding History

SUNPHARMA Shareholding History

Dec '24MarJunSepDec '25Mar18.05%17.96%17.26%16.55%16.12%15.93%

Mutual Funds Invested in SUNPHARMA

Mutual Funds Invested in SUNPHARMA

No mutual funds holding trends are available

Top 5 Mutual Funds holding Sun Pharmaceutical Industries Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
0.6206%4.79%-0.08%5/93 (0)
0.4132%2.52%-0.29%11/104 (0)
0.3994%3.60%-0.93%3/279 (+1)

Compare 3-month MF holding change on Screener

SUNPHARMA Insider Trades & Bulk Stock Deals

SUNPHARMA Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing SUNPHARMA stock

smallcases containing SUNPHARMA stock

A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Sun Pharmaceutical Industries Ltd

Loading...
Pharma Tracker

Pharma Tracker

Created by Windmill Capital

SUNPHARMA's Wtg.
10.55%
10.55%
CAGR
18.83%

SUNPHARMA Events

SUNPHARMA Events

SUNPHARMA Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

SUNPHARMA has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.83%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹8.33 every year

Dividends

Corp. Actions

Announcements

Legal Orders

SUNPHARMA Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

SUNPHARMA has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.83%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹8.33 every year

SUNPHARMA Upcoming Dividends

SUNPHARMA Upcoming Dividends

No upcoming dividends are available

SUNPHARMA Past Dividends

SUNPHARMA Past Dividends

Cash Dividend

Ex DateEx DateJul 7, 2026

Final
Final | Div/Share: ₹5.00

Dividend/Share

5.00

Ex DateEx Date

Jul 7, 2026

Cash Dividend

Ex DateEx DateFeb 5, 2026

Interim
Interim | Div/Share: ₹11.00

Dividend/Share

11.00

Ex DateEx Date

Feb 5, 2026

Cash Dividend

Ex DateEx DateJul 7, 2025

Final
Final | Div/Share: ₹5.50

Dividend/Share

5.50

Ex DateEx Date

Jul 7, 2025

Cash Dividend

Ex DateEx DateFeb 6, 2025

Interim
Interim | Div/Share: ₹10.50

Dividend/Share

10.50

Ex DateEx Date

Feb 6, 2025

Cash Dividend

Ex DateEx DateJul 12, 2024

Final
Final | Div/Share: ₹5.00

Dividend/Share

5.00

Ex DateEx Date

Jul 12, 2024

SUNPHARMA Stock News & Opinions

SUNPHARMA Stock News & Opinions

Corporate
Corporate
Sun Pharmaceuticals Industries announces board meeting date

Sun Pharmaceuticals Industries will hold a meeting of the Board of Directors of the Company on 31 July 2026.

2 days agoCapital Market - Live
Spotlight
Spotlight
Sun Pharmaceutical Industries Ltd spurts 0.07%, up for five straight sessions

Sun Pharmaceutical Industries Ltd rose for a fifth straight session today. The stock is quoting at Rs 1914.2, up 0.07% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.17% on the day, quoting at 24472.4. The Sensex is at 78420.16, up 0.17%. Sun Pharmaceutical Industries Ltd has added around 7.01% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has added around 6.88% in last one month and is currently quoting at 25866.25, down 0.22% on the day. The volume in the stock stood at 10.77 lakh shares today, compared to the daily average of 19.54 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 1917.1, down 0.05% on the day. Sun Pharmaceutical Industries Ltd is up 14.45% in last one year as compared to a 4.11% fall in NIFTY and a 16.43% fall in the Nifty Pharma index.The PE of the stock is 152.92 based on TTM earnings ending March 26.Powered by Capital Market - Live

6 days agoCapital Market - Live
Spotlight
Spotlight
Sun Pharmaceutical Industries Ltd spurts 2.14%

Sun Pharmaceutical Industries Ltd is up for a third straight session in a row. The stock is quoting at Rs 1911.1, up 2.14% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.74% on the day, quoting at 24354.25. The Sensex is at 78056.84, up 0.72%. Sun Pharmaceutical Industries Ltd has risen around 7.36% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has risen around 6.77% in last one month and is currently quoting at 25308.9, up 2% on the day. The volume in the stock stood at 15.41 lakh shares today, compared to the daily average of 20.27 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 1915.8, up 2.17% on the day. Sun Pharmaceutical Industries Ltd is up 14.01% in last one year as compared to a 4.35% drop in NIFTY and a 15.33% drop in the Nifty Pharma index.The PE of the stock is 149.6 based on TTM earnings ending March 26.Powered by Capital Market - Live

1 week agoCapital Market - Live
Spotlight
Spotlight
Sun Pharmaceutical Industries Ltd spurts 1.19%, rises for fifth straight session

Sun Pharmaceutical Industries Ltd gained for a fifth straight session today. The stock is quoting at Rs 1885, up 1.19% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.64% on the day, quoting at 23948.45. The Sensex is at 76610.4, down 0.63%. Sun Pharmaceutical Industries Ltd has risen around 2.41% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has risen around 1.62% in last one month and is currently quoting at 24762.9, up 1.26% on the day. The volume in the stock stood at 16.35 lakh shares today, compared to the daily average of 26.88 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 1883.8, up 1.11% on the day. Sun Pharmaceutical Industries Ltd is up 13.44% in last one year as compared to a 4.38% drop in NIFTY and a 15.7% drop in the Nifty Pharma index.The PE of the stock is 148.96 based on TTM earnings ending March 26.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Spotlight
Spotlight
Sun Pharma to acquire 100% stake in Innovcare Lifesciences for Rs 271 crore

Innovcare Lifesciences is engaged in the business of marketing, distribution and sale of pharmaceutical drugs, nutraceutical and cosmeceutical products. The revenue from operations for FY 2025-26 was Rs 94.06 crore. Sun Pharma stated that this acquisition is being done to strengthen product portfolio of the company. The company expects to complete this transaction before 31 July 2026. Sun Pharmaceutical Industries is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and active pharmaceutical ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world, with trading and other incidental and related activities extending to global market. It is the largest pharmaceutical company in India. The company had reported 26.24% rise in consolidated net profit to Rs 2,714.03 crore in Q4 FY26 as against Rs 2,149.88 crore posted in the same period year ago. Total revenue from operations increased 12.75% YoY to Rs 14,611.79 crore in the quarter ended 31 March 2026. The scrip advanced 0.85% to currently trade at Rs 1852.70 on the BSE. Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Spotlight
Spotlight
Stock Alert: Sun Pharma, GRSE, GE Power, Goodluck India, Zaggle Prepaid, Texmaco Rail

Securities in F&O Ban: Shares of Kaynes Technology India are banned from F&O trading on 22 June 2026. Stocks to Watch: Sun Pharmaceuticals Industries has entered into an agreement to acquire 100% stake in Innovcare Lifesciences, based in Mumbai and engaged in the business of marketing, distribution and sale of pharmaceutical drugs, nutraceutical and cosmeceutical products. The total consideration of the transaction is valued at Rs 271.2 crore. Garden Reach Shipbuilders & Engineers (GRSE) has been granted Navratna status by the Department of Public Enterprises (DPE) under the Ministry of Finance. The company said the recognition reflects its strong financial performance, operational efficiency and contribution to national security. GE Power India announced a series of senior leadership changes, including the appointment of Rahul Rojal as Chief Financial Officer (CFO), as the company strengthens its management team amid ongoing business and project execution initiatives. Goodluck India announced that its subsidiary, Goodluck Defence and Aerospace, has secured an order worth approximately Rs 255 crore for the supply of 155 mm long-range empty shells in ready-to-fill condition. Zaggle Prepaid Ocean Services (Zaggle) announced that it has entered into an agreement with Punjab National Bank (PNB) to act as a co-branding partner for a retail credit card product. Under the agreement, Zaggle will leverage its existing corporate customer base to drive acquisition, marketing and promotion of the co-branded retail credit card. The partnership is aimed at expanding the reach of the co-branded card offering. Texmaco Rail & Engineering has received a letter of intent (LoI) worth Rs 253.28 crore from JSW (South) Rail Logistics for the manufacture and supply of BFNSM1 rakes along with BVCM wagons. The domestic order is scheduled to be executed within 13.5 months from the effective date or commencement of work.Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Corporate
Sun Pharmaceuticals Industries schedules AGM

Sun Pharmaceuticals Industries announced that the 34th Annual General Meeting(AGM) of the company will be held on 31 July 2026.

1 month agoCapital Market - Live
Corporate
Corporate
Sun Pharmaceutical Industries fixes record date for final dividend

Sun Pharmaceutical Industries has fixed 07 July 2026 as record date for determining the entitlement of shareholders to receive the final dividend of Rs 5 per equity share for the financial year 20225-26. The payment of the said final dividend, if approved by the shareholders at the AGM, will be made on or before 07 August 2026

1 month agoCapital Market - Live
Spotlight
Spotlight
Sun Pharmaceutical Industries Ltd drops for fifth straight session

Sun Pharmaceutical Industries Ltd fell for a fifth straight session today. The stock is quoting at Rs 1774.1, down 0.81% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.22% on the day, quoting at 23353.3. The Sensex is at 74101.32, down 0.33%.Sun Pharmaceutical Industries Ltd has eased around 2.56% in last one month.Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has increased around 2.59% in last one month and is currently quoting at 24086.6, up 0.38% on the day. The volume in the stock stood at 11.66 lakh shares today, compared to the daily average of 29.77 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 1793.9, down 0.5% on the day. Sun Pharmaceutical Industries Ltd jumped 5.41% in last one year as compared to a 5.65% slide in NIFTY and a 11.71% spurt in the Nifty Pharma index.The PE of the stock is 143.04 based on TTM earnings ending March 26.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Corporate
Board of Sun Pharmaceuticals Industries recommends final dividend

Sun Pharmaceuticals Industries announced that the Board of Directors of the Company at its meeting held on 22 May 2026, inter alia, have recommended the final dividend of Rs 5 per equity Share (i.e. 500%) , subject to the approval of the shareholders.

1 month agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Sun Pharmaceutical Industries Ltd (SUNPHARMA) today?

    The share price of SUNPHARMA as on 14th July 2026 is ₹1925.30. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Sun Pharmaceutical Industries Ltd (SUNPHARMA) share?

    The past returns of Sun Pharmaceutical Industries Ltd (SUNPHARMA) share are
    • Past 1 week: 0.87%
    • Past 1 month: 5.69%
    • Past 3 months: 16.29%
    • Past 6 months: 11.15%
    • Past 1 year: 14.19%
    • Past 3 years: 78.63%
    • Past 5 years: 181.32%

  3. What are the peers or stocks similar to Sun Pharmaceutical Industries Ltd (SUNPHARMA)?

    The peers or stocks similar to Sun Pharmaceutical Industries Ltd (SUNPHARMA) include:

  4. What is the dividend yield % of Sun Pharmaceutical Industries Ltd (SUNPHARMA) share?

    The current dividend yield of Sun Pharmaceutical Industries Ltd (SUNPHARMA) is 0.83.

  5. What is the market cap of Sun Pharmaceutical Industries Ltd (SUNPHARMA) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sun Pharmaceutical Industries Ltd (SUNPHARMA) is ₹461008.22 Cr as of 14th July 2026.

  6. What is the 52 week high and low of Sun Pharmaceutical Industries Ltd (SUNPHARMA) share?

    The 52-week high of Sun Pharmaceutical Industries Ltd (SUNPHARMA) is ₹1953.90 and the 52-week low is ₹1548.

  7. What is the PE and PB ratio of Sun Pharmaceutical Industries Ltd (SUNPHARMA) stock?

    The P/E (price-to-earnings) ratio of Sun Pharmaceutical Industries Ltd (SUNPHARMA) is 40.16. The P/B (price-to-book) ratio is 5.50.

  8. Which sector does Sun Pharmaceutical Industries Ltd (SUNPHARMA) belong to?

    Sun Pharmaceutical Industries Ltd (SUNPHARMA) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  9. How to buy Sun Pharmaceutical Industries Ltd (SUNPHARMA) shares?

    You can directly buy Sun Pharmaceutical Industries Ltd (SUNPHARMA) shares on Tickertape. Simply sign up, connect your demat account and place your order.